吉林大学学报(医学版)

• 基础研究 • 上一篇    下一篇

初治急性髓系白血病患者CEBPA基因突变检测及其临床意义

胡瑞萍1,崔久嵬,李薇1,张福明1,韩薇1,杜忠华1,韩秀丽1,刘晓玲1,李红兵1,续薇2   

  1. 1.吉林大学第一医院肿瘤中心,吉林 长春 130021;2.吉林大学第一医院检验科,吉林 长春 130021
  • 收稿日期:2013-11-14 出版日期:2014-03-28 发布日期:2014-05-28
  • 通讯作者: 续 薇(Tel :0431-88782622,E-mail:xuwei0210@sina.com ) E-mail:xuwei0210@sina.com
  • 作者简介:胡瑞萍(1983-),女,吉林省长春市人,技师,医学硕士,主要从事肿瘤与白血病基因的研究。
  • 基金资助:

    吉林省科技厅中青年领军人才创新团队项目资助课题(20111807)

Detection of CEBPA gene mutation in patients with newly diagnosed   acute myeloid leukemia and its clinical significance

HU Rui-ping1,CUI Jiu-wei1,LI Wei1,ZHANG Fu-ming1,HAN Wei1,DU Zhong-hua1,HAN Xiu-li1,LIU Xiao-ling1,LI Hong-bing1,XU Wei2   

  1. 1.Tumor Center,First Hospital,Jilin University,Changchun 130021,China; 2.Department of Laboratory,First Hospital,Jilin University,Changchun 130021,China
  • Received:2013-11-14 Online:2014-03-28 Published:2014-05-28

摘要:

目的:探讨急性髓系白血病(AML)患者CCAAT/增强子结合蛋白-α(CEBPA)基因突变的情况,阐明其临床意义。方法:无菌采集279例AML患者和40名对照者骨髓或外周血样本,瑞士染色分析细胞形态学及骨髓幼稚细胞(BM Blast)比例;采用PCR联合序列分析法检测CEBPA、FLT3-ITD、NPM1和C-KIT基因突变情况;G显带技术进行染色体核型分析。结果:279例初治AML患者中35例检测到CEBPA基因突变,总检出率为12.5%,其在M2型患者中的检出率显著高于其他亚型(P<0.05)。35例突变患者中31例为双突变,其余4例为单突变,对照者CEBPA突变均为阴性。CEBPA基因突变常见于正常核型患者。与CEBPA野生型患者比较,CEBPA双突变患者的白细胞(WBC)计数、红细胞(RBC)计数及血红蛋白(HGB)水平升高(P<0.05),年龄、血小板(PLT)计数降低(P<0.05),而性别、BM blast比例及FLT3-ITD、NPM1、C-KIT基因突变发生率组间比较差异无统计学意义(P>0.05)。在治疗方面,CEBPA双突变型与野生型患者首疗程诱导缓解率分别为84.0%和80.5% (P>0.05)。结论:CEBPA基因突变主要见于M2亚型的AML患者,常见突变形式为双等位基因突变,CEBPA双突变型与野生型患者有不同临床特征,表现为WBC、RBC计数和HGB水平较高,年龄和PLT计数较低。

关键词: 白血病, 急性髓系, CCAAT/增强子结合蛋白-&alpha, 基因突变, 序列分析

Abstract:

Objective To investigate the CCAAT-enhancer binding protein-alpha(CEBPA) gene mutation in the patients with acute myeloid leukemia( AML) and to clarify its clinical significance.Methods The bone marrow or peripheral blood samples were collected from 279 AML patients and 40 healthy volunteers, respectively.The cell morphology and the proportion of  bone marrow blast counts (BM blast) were observed by Switzerland staining.CEBPA,FLT3-ITD,NPM1 and C-KIT gene mutations were detected by PCR and sequence analysis.Karyotype analysis was performed by  G-banding technique.Results Among 279 newly diagnosed  AML patients,35(12.5%) had CEBPA gene mutation.The detection rate in M2 subtype patients was significantly higher than those in other subtypes patients(P<0.05).Of 35 CEBPA mutation patients,31 had double mutations, and the remaining 4 had single mutation.CEBPA mutations were all negative in 40 healthy volunteers.CEBPA mutation was common in normal karyotype patients. Compared with the patients with  wild-type CEBPA gene,the patients with CEBPA double mutations had higher white blood cell(WBC) count,red blood cell (RBC) count,and hemoglobin (HGB) level (P<0.05)  and lower age and platelet(PLT) count(P<0.05).However,there was no difference between the patients with and without CEBPA mutation in the gender,proportion of BM blast   and the incidence of FLT3-ITD,NPM1,and C-KIT gene mutations (P>0.05).In terms of treatment,the remission rates of first induction treatment were 84.0% and 80.5% in CEBPA double mutation and wild-type patients,there was no statistically significant difference between two groups (P> 0.05).Conclusion CEBPA gene mutation is mainly seen in M2 subtype AML patients.CEBPA common mutation is biallelic mutation.CEBPA double mutation and wild-type patients have different clinical characteristics.The patients with CEBPA double mutations have higher WBC   count,RBC count,and HGB level and lower age and PLT count.

Key words: leukemia,acute myeloid, CCAAT-enhancer binding protein-alpha, gene mutation, sequence analysis

中图分类号: 

  • R733